COMPLETED RESEARCH: CLINICAL/TRANSLATIONAL RESEARCH
Abstract #CT08

In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Clinical Trials, Multiple Myeloma

Presenter: Joshua Richter, MD, Assistant Professor of Medicine, Icahn School of Medicine at Mount Sinai

Co-Authors: Habte A. Yimer, Texas Oncology/US Oncology Research, Tyler, TX; Stephen J. Noga, Millennium Pharmaceuticals, Cambridge, MA, a wholly owned subsidiary of Takeda; Sudhir Manda, Arizona Oncology/US Oncology Research, Tucson, AZ; Roger M. Lyons, Texas Oncology/US Oncology Research, San Antonio, TX; Kimberly Bogard, Millennium Pharmaceuticals, Cambridge, MA, a wholly owned subsidiary of Takeda; Presley Whidden, Millennium Pharmaceuticals, Cambridge, MA, a wholly owned subsidiary of Takeda; Dasha Cherepanov, Millennium Pharmaceuticals, Cambridge, MA, a wholly owned subsidiary of Takeda; Jack Aiello, Patient Empowerment Network, San Jose, CA; Saulius Girnius, Trihealth Cancer Institute, Cincinnati, OH; Robert M. Rifkin, Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO

Background: Long-term proteasome inhibitor (PI)-based treatment is associated with improved outcomes in multiple myeloma. However, prolonged therapy with parenteral PIs can be challenging. The US MM-6 study (NCT03173092) is investigating in-class transition from parenteral bortezomib-based induction to all-oral ixazomib-lenalidomide-dexamethasone (IRd) in US community patients, with the aim of increasing PI-based treatment duration, while maintaining quality of life and improving outcomes.

Objectives: The primary end point is progression-free survival (PFS); key secondary end points include rate of partial response, very good partial response (VGPR), and complete response (CR) rates, as well as duration of therapy.

Methods: Transplant-ineligible patients or patients with delayed (>24 months) newly diagnosed multiple myeloma and stable disease or better after 3 cycles of bortezomib-based induction are being enrolled to undergo in-class transition and receive IRd (up to 39 28-day cycles or until disease progression or unacceptable toxicity).

Results: At data cutoff, 101 patients had received treatment. The patients’ median age is 73 years; 46% are aged ≥75 years; 16% are black/African American; 10% are Hispanic/Latino; 26% have calculated creatinine clearance <60 mL/min. At the start of IRd therapy, 95% of patients had ≥1 comorbidities, including renal and urinary disorders (38%), cardiac disorders (29%), and peripheral neuropathy (14%). With 52% of the patients continuing therapy and the enrollment is ongoing, the mean duration of therapy from the start of bortezomib-based induction was 12.4 months; mean IRd duration of therapy after in-class transition was 9.2 months. Patients have received IRd for up to 29.4 months to date. The overall response rate (ORR) after bortezomib-based induction was 62% (7% CR, 32% ≥VGPR). After in-class transition, the ORR increased to 71%, and the CR and ≥VGPR rates increased to 29% and 53%, respectively. The 12-month PFS rate was 84% from the start of bortezomib-based induction and 80% from the start of IRd. During IRd treatment to date, 91% of patients have had treatment-emergent adverse events (AEs; 53% grade ≥3). Treatment-emergent AEs led to study-drug modification and discontinuation in 52% and 7% of patients, respectively. Serious treatment-emergent AEs occurred in 37% of the patients. Diarrhea, peripheral neuropathy, nausea, and vomiting occurred in 43% (8% grade 3), 32% (2%), 23% (2%), and 14% (2%) of patients, respectively. Other (≥5%) grade 3 treatment-emergent AEs were pneumonia (7%) and syncope (5%).

Conclusion: Patients in the US MM-6 study reflect the real-world US population with multiple myeloma, including mostly elderly, comorbid, community-based patients with newly diagnosed multiple myeloma. In-class transition to IRd after 3 cycles of bortezomib-based induction resulted in improved response rates and depths of responses, as well as prolonged duration of therapy, and may thereby improve outcomes for real-world patients. In-class transition to an all-oral regimen could also prevent treatment interruptions for patients who are unable to, or prefer not to, travel regularly to a clinic for treatment.

Related Items
Abecma First CAR T-Cell Therapy Approved for Multiple Myeloma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Multiple Myeloma
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Multiple Myeloma
Welcome to the First Annual Issue of HOPA Abstracts, 2021
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts
Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Patients with Multiple Myeloma Receiving Lenalidomide, Bortezomib, and Dexamethasone
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Multiple Myeloma
Correlation of BRAF Mutation Status in Circulating Tumor DNA with Tumor Biopsy and Clinical Outcomes in the COLUMBUS Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Targeted Therapies
Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Cost of Cancer Management by Stage of Diagnosis Among Medicare Beneficiaries
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Cost of Care
Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600E–Positive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Colorectal Cancer
Incidence of Adverse Effects in Patients with Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Lymphoid Blast Crisis Receiving Ponatinib with or without Concomitant Azole Antifungals
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Leukemia
Real-World Dosing Patterns of Ruxolitinib Among Patients with Myelofibrosis: A US Community Oncology Practice
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Oncology Pharmacy Programs, Myelofibrosis
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.